CLARITY PHARMACEUTICALS Mediaroom

Clarity signs copper-67 Supply Agreement with Nusano

SYDNEY, Oct. 16, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), ...

2025-10-16 21:04 1277

Co-PSMA trial achieves primary endpoint

SYDNEY, Oct. 14, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), ...

2025-10-14 21:03 1199

Co-PSMA trial: Recruitment successfully completed

SYDNEY, July 17, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), ...

2025-07-17 21:01 1995

Clarity enters a Commercial Manufacturing Agreement for Cu-64 SAR-bisPSMA with SpectronRx

Highlights * Clarity has entered into a Commercial Manufacturing Agreement with SpectronRx for64...

2025-06-17 21:04 1872

SABRE topline results: Cu-64 SAR-Bombesin is effective in detecting prostate cancer recurrence in patients with negative SOC imaging

Highlights * Topline data from Clarity's diagnostic Phase II trial, SABRE, showed that 64 Cu-SAR-...

2025-06-13 21:01 2409

SABRE topline results: Cu-64 SAR-Bombesin is effective in detecting prostate cancer recurrence in patients with negative SOC imaging

DISCO topline results: 64Cu-SARTATE is highly effective in detecting tumours in NET patients compared to SOC imaging. Phase III planning underway.

HIGHLIGHTS * Topline data from Clarity's diagnostic Phase II trial, DISCO, confirms that 64Cu-SA...

2025-06-05 21:01 2351

DISCO topline results: 64Cu-SARTATE is highly effective in detecting tumours in NET patients compared to SOC imaging. Phase III planning underway.

First patient imaged in Phase III AMPLIFY trial with 64Cu-SAR-bisPSMA PET/CT

SYDNEY, May 29, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a...

2025-05-29 21:04 1897

Registrational Phase III AMPLIFY trial in biochemical recurrence of prostate cancer commences

SYDNEY, May 20, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a...

2025-05-20 21:02 2015

Clarity signs high-volume commercial-scale copper-64 Supply Agreement with Nusano

Highlights * Clarity has signed a commercial-scale agreement with Nusano, Inc. ("Nusano") for su...

2025-04-17 21:01 2852

SECuRE trial update: First patient treated in the Phase II Cohort Expansion

HIGHLIGHTS * The first of the planned 24 participants in the Cohort Expansion Phase (Phase II) o...

2025-04-15 21:02 2174

SECuRE trial update: 92% of pre-chemo participants experience greater than 35% drop in PSA levels across all cohorts. Cohort Expansion Phase commences.

HIGHLIGHTS * Safety Review Committee (SRC) meeting confirms end of the Dose Escalation Phase and...

2025-03-05 21:44 2623

Clarity receives US FDA Fast Track Designation for the treatment of metastatic castration-resistant prostate cancer patients with Cu-67 SAR-bisPSMA

SYDNEY, Feb. 19, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), ...

2025-02-19 22:09 2703

Clarity receives U.S. FDA Fast Track Designation for Cu-64 SAR-bisPSMA in biochemical recurrence of prostate cancer

SYDNEY, Jan. 24, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), ...

2025-01-24 22:02 4688

Clarity expands its pipeline with a novel optimised FAP-targeted radiopharmaceutical

Highlights * Clarity has developed a proprietary fibroblast activation protein (FAP)-targeted ra...

2024-12-18 22:03 2191

Copper-67 SAR-bisPSMA updates

SYDNEY, Oct. 16, 2024 /PRNewswire/ -- HIGHLIGHTS Cohort 4 - SECuRE Trial * The third participa...

2024-10-16 21:03 3025

Positive guidance from the U.S. FDA on 64Cu-SAR-bisPSMA Phase III trial in patients with recurrence of prostate cancer

Highlights * United States Food and Drug Administration (U.S. FDA) provided positive feedback on...

2024-10-14 21:02 2425

SECuRE trial advances: No dose limiting toxicities and strong preliminary efficacy data in first multi-dose cohort

Highlights * Cohort 4 of the SECuRE trial is the first to assess multiple cycles of 67 Cu-SAR-bis...

2024-09-12 21:03 2386

SECuRE trial advances: No dose limiting toxicities and strong preliminary efficacy data in first multi-dose cohort

Clarity receives FDA Fast Track Designation for 64Cu-SAR-bisPSMA

SYDNEY, Aug. 22, 2024 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-st...

2024-08-22 21:04 2722

Additional COBRA results: SAR-bisPSMA detects lesions in the 2-millimetre range

Highlights * Clarity recently reported that in its diagnostic Phase 1/2 trial, COBRA, 64 Cu-SAR-b...

2024-03-08 22:02 2687

Additional COBRA results: SAR-bisPSMA detects lesions in the 2-millimetre range

Registrational Phase III CLARIFY trial in prostate cancer commences

SYDNEY, Nov. 30, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical st...

2023-11-30 22:16 2017

Latest News